IBDEI02X ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3399,0)
 ;;=V10.44^^29^267^18
 ;;^UTILITY(U,$J,358.3,3399,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3399,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,3399,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,3399,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,3400,0)
 ;;=V10.81^^29^267^2
 ;;^UTILITY(U,$J,358.3,3400,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3400,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,3400,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,3400,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,3401,0)
 ;;=V10.82^^29^267^25
 ;;^UTILITY(U,$J,358.3,3401,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3401,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,3401,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,3401,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,3402,0)
 ;;=V10.83^^29^267^31
 ;;^UTILITY(U,$J,358.3,3402,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3402,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,3402,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,3402,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,3403,0)
 ;;=V10.84^^29^267^6
 ;;^UTILITY(U,$J,358.3,3403,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3403,1,1,0)
 ;;=1^V10.84
 ;;^UTILITY(U,$J,358.3,3403,1,8,0)
 ;;=8^Hx Of Eye Malignancy
 ;;^UTILITY(U,$J,358.3,3403,2)
 ;;=^295242
 ;;^UTILITY(U,$J,358.3,3404,0)
 ;;=V10.85^^29^267^3
 ;;^UTILITY(U,$J,358.3,3404,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3404,1,1,0)
 ;;=1^V10.85
 ;;^UTILITY(U,$J,358.3,3404,1,8,0)
 ;;=8^Hx Of Brain Malignancy
 ;;^UTILITY(U,$J,358.3,3404,2)
 ;;=^295243
 ;;^UTILITY(U,$J,358.3,3405,0)
 ;;=V10.86^^29^267^26
 ;;^UTILITY(U,$J,358.3,3405,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3405,1,1,0)
 ;;=1^V10.86
 ;;^UTILITY(U,$J,358.3,3405,1,8,0)
 ;;=8^Hx-Malign Nerve Syst Nec
 ;;^UTILITY(U,$J,358.3,3405,2)
 ;;=^295244
 ;;^UTILITY(U,$J,358.3,3406,0)
 ;;=V10.88^^29^267^16
 ;;^UTILITY(U,$J,358.3,3406,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3406,1,1,0)
 ;;=1^V10.88
 ;;^UTILITY(U,$J,358.3,3406,1,8,0)
 ;;=8^Hx-Endocrine Malign Nec
 ;;^UTILITY(U,$J,358.3,3406,2)
 ;;=^295246
 ;;^UTILITY(U,$J,358.3,3407,0)
 ;;=238.0^^29^268^1
 ;;^UTILITY(U,$J,358.3,3407,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3407,1,1,0)
 ;;=1^238.0
 ;;^UTILITY(U,$J,358.3,3407,1,8,0)
 ;;=8^Bone and Articular Cartilage
 ;;^UTILITY(U,$J,358.3,3407,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,3408,0)
 ;;=238.1^^29^268^3
 ;;^UTILITY(U,$J,358.3,3408,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3408,1,1,0)
 ;;=1^238.1
 ;;^UTILITY(U,$J,358.3,3408,1,8,0)
 ;;=8^Connective and Oth Soft Tissue
 ;;^UTILITY(U,$J,358.3,3408,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,3409,0)
 ;;=238.2^^29^268^17
 ;;^UTILITY(U,$J,358.3,3409,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3409,1,1,0)
 ;;=1^238.2
 ;;^UTILITY(U,$J,358.3,3409,1,8,0)
 ;;=8^Skin
 ;;^UTILITY(U,$J,358.3,3409,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,3410,0)
 ;;=238.3^^29^268^2
 ;;^UTILITY(U,$J,358.3,3410,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3410,1,1,0)
 ;;=1^238.3
 ;;^UTILITY(U,$J,358.3,3410,1,8,0)
 ;;=8^Breast
 ;;^UTILITY(U,$J,358.3,3410,2)
 ;;=^81956
 ;;^UTILITY(U,$J,358.3,3411,0)
 ;;=238.4^^29^268^15
 ;;^UTILITY(U,$J,358.3,3411,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3411,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,3411,1,8,0)
 ;;=8^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,3411,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,3412,0)
 ;;=238.5^^29^268^6
 ;;^UTILITY(U,$J,358.3,3412,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3412,1,1,0)
 ;;=1^238.5
 ;;^UTILITY(U,$J,358.3,3412,1,8,0)
 ;;=8^Histiocytic and Mast Cells
 ;;^UTILITY(U,$J,358.3,3412,2)
 ;;=^267778
 ;;^UTILITY(U,$J,358.3,3413,0)
 ;;=238.6^^29^268^14
 ;;^UTILITY(U,$J,358.3,3413,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3413,1,1,0)
 ;;=1^238.6
 ;;^UTILITY(U,$J,358.3,3413,1,8,0)
 ;;=8^Plasma Cells
 ;;^UTILITY(U,$J,358.3,3413,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,3414,0)
 ;;=238.71^^29^268^4
 ;;^UTILITY(U,$J,358.3,3414,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3414,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,3414,1,8,0)
 ;;=8^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,3414,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,3415,0)
 ;;=238.72^^29^268^7
 ;;^UTILITY(U,$J,358.3,3415,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3415,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,3415,1,8,0)
 ;;=8^Low Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,3415,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,3416,0)
 ;;=238.73^^29^268^5
 ;;^UTILITY(U,$J,358.3,3416,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3416,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,3416,1,8,0)
 ;;=8^High Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,3416,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,3417,0)
 ;;=238.74^^29^268^9
 ;;^UTILITY(U,$J,358.3,3417,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3417,1,1,0)
 ;;=1^238.74
 ;;^UTILITY(U,$J,358.3,3417,1,8,0)
 ;;=8^Myelody Synd w/ 5q Deletion
 ;;^UTILITY(U,$J,358.3,3417,2)
 ;;=^334030
 ;;^UTILITY(U,$J,358.3,3418,0)
 ;;=238.75^^29^268^10
 ;;^UTILITY(U,$J,358.3,3418,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3418,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,3418,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,3418,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,3419,0)
 ;;=238.76^^29^268^11
 ;;^UTILITY(U,$J,358.3,3419,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3419,1,1,0)
 ;;=1^238.76
 ;;^UTILITY(U,$J,358.3,3419,1,8,0)
 ;;=8^Myelofibrosis w/Myeloid Metaplasia
 ;;^UTILITY(U,$J,358.3,3419,2)
 ;;=^334032
 ;;^UTILITY(U,$J,358.3,3420,0)
 ;;=238.77^^29^268^16
 ;;^UTILITY(U,$J,358.3,3420,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3420,1,1,0)
 ;;=1^238.77
 ;;^UTILITY(U,$J,358.3,3420,1,8,0)
 ;;=8^Post Transp Lymphoprolif d/o PTLD
 ;;^UTILITY(U,$J,358.3,3420,2)
 ;;=^336526
 ;;^UTILITY(U,$J,358.3,3421,0)
 ;;=238.79^^29^268^12
 ;;^UTILITY(U,$J,358.3,3421,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3421,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,3421,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue
 ;;^UTILITY(U,$J,358.3,3421,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,3422,0)
 ;;=238.8^^29^268^13
 ;;^UTILITY(U,$J,358.3,3422,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3422,1,1,0)
 ;;=1^238.8
 ;;^UTILITY(U,$J,358.3,3422,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,3422,2)
 ;;=^267779
 ;;^UTILITY(U,$J,358.3,3423,0)
 ;;=238.9^^29^268^8
 ;;^UTILITY(U,$J,358.3,3423,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3423,1,1,0)
 ;;=1^238.9
 ;;^UTILITY(U,$J,358.3,3423,1,8,0)
 ;;=8^Lymph/Hematopoietic Tissue NOS
 ;;^UTILITY(U,$J,358.3,3423,2)
 ;;=^267780
 ;;^UTILITY(U,$J,358.3,3424,0)
 ;;=239.0^^29^269^5
 ;;^UTILITY(U,$J,358.3,3424,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3424,1,1,0)
 ;;=1^239.0
 ;;^UTILITY(U,$J,358.3,3424,1,8,0)
 ;;=8^Digestive Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3424,2)
 ;;=^267781
 ;;^UTILITY(U,$J,358.3,3425,0)
 ;;=239.1^^29^269^11
 ;;^UTILITY(U,$J,358.3,3425,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3425,1,1,0)
 ;;=1^239.1
 ;;^UTILITY(U,$J,358.3,3425,1,8,0)
 ;;=8^Respiratory Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3425,2)
 ;;=^267782
 ;;^UTILITY(U,$J,358.3,3426,0)
 ;;=239.2^^29^269^2
 ;;^UTILITY(U,$J,358.3,3426,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3426,1,1,0)
 ;;=1^239.2
 ;;^UTILITY(U,$J,358.3,3426,1,8,0)
 ;;=8^Bone,Soft Tissue,Skin Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3426,2)
 ;;=^267783
 ;;^UTILITY(U,$J,358.3,3427,0)
 ;;=239.3^^29^269^4
 ;;^UTILITY(U,$J,358.3,3427,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3427,1,1,0)
 ;;=1^239.3
 ;;^UTILITY(U,$J,358.3,3427,1,8,0)
 ;;=8^Breast Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3427,2)
 ;;=^81977
 ;;^UTILITY(U,$J,358.3,3428,0)
 ;;=239.4^^29^269^1
 ;;^UTILITY(U,$J,358.3,3428,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3428,1,1,0)
 ;;=1^239.4
 ;;^UTILITY(U,$J,358.3,3428,1,8,0)
 ;;=8^Bladder Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3428,2)
 ;;=^81975
 ;;^UTILITY(U,$J,358.3,3429,0)
 ;;=239.5^^29^269^9
 ;;^UTILITY(U,$J,358.3,3429,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3429,1,1,0)
 ;;=1^239.5
 ;;^UTILITY(U,$J,358.3,3429,1,8,0)
 ;;=8^Oth Genitourinary Org Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3429,2)
 ;;=^267784
 ;;^UTILITY(U,$J,358.3,3430,0)
 ;;=239.6^^29^269^3
 ;;^UTILITY(U,$J,358.3,3430,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3430,1,1,0)
 ;;=1^239.6
 ;;^UTILITY(U,$J,358.3,3430,1,8,0)
 ;;=8^Brain Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3430,2)
 ;;=^16739
 ;;^UTILITY(U,$J,358.3,3431,0)
 ;;=239.7^^29^269^6
 ;;^UTILITY(U,$J,358.3,3431,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3431,1,1,0)
 ;;=1^239.7
 ;;^UTILITY(U,$J,358.3,3431,1,8,0)
 ;;=8^Endocrine/Nerv Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3431,2)
 ;;=^267785
 ;;^UTILITY(U,$J,358.3,3432,0)
 ;;=239.81^^29^269^12
 ;;^UTILITY(U,$J,358.3,3432,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3432,1,1,0)
 ;;=1^239.81
 ;;^UTILITY(U,$J,358.3,3432,1,8,0)
 ;;=8^Retina/Choroid Neoplasm NOS
 ;;^UTILITY(U,$J,358.3,3432,2)
 ;;=^338224
 ;;^UTILITY(U,$J,358.3,3433,0)
 ;;=239.89^^29^269^7
 ;;^UTILITY(U,$J,358.3,3433,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3433,1,1,0)
 ;;=1^239.89
 ;;^UTILITY(U,$J,358.3,3433,1,8,0)
 ;;=8^Neoplasm,Oth Spec Sites
 ;;^UTILITY(U,$J,358.3,3433,2)
 ;;=^338225
 ;;^UTILITY(U,$J,358.3,3434,0)
 ;;=239.9^^29^269^8
 ;;^UTILITY(U,$J,358.3,3434,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3434,1,1,0)
 ;;=1^239.9
 ;;^UTILITY(U,$J,358.3,3434,1,8,0)
 ;;=8^Neoplasm,Unspec Site 
 ;;^UTILITY(U,$J,358.3,3434,2)
 ;;=^82022
 ;;^UTILITY(U,$J,358.3,3435,0)
 ;;=288.9^^29^269^15
 ;;^UTILITY(U,$J,358.3,3435,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3435,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,3435,1,8,0)
 ;;=8^Unspec Dis of WBC
 ;;^UTILITY(U,$J,358.3,3435,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,3436,0)
 ;;=289.0^^29^269^13
 ;;^UTILITY(U,$J,358.3,3436,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3436,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,3436,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,3436,2)
 ;;=^186856
